3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
4
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Pancreatic Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Appendiceal Neoplasms
1
Interventions
Gemcitabine
8
Cystectomy
6
Cisplatin
5
Mitomycin
3
toripalimab
2
tislelizumab
2
disitamab vedotin
2
Radiotherapy
2
Radiosurgery
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
zimberelimab
1
trilaciclib
1
sacituzumab govitecan
1
nimotuzumab
1
entinostat
1
durvalumab
1
cemiplimab
1
Transurethral Resection of Bladder
1
Therapeutics
1
Synapsins
1
Saline Solution
1
Radiotherapy, Intensity-Modulated
1
RC48 antibody
1
Olive Oil
1
Niacinamide
1
Niacin
1
Music Therapy
1
Liquid Biopsy
1
Immunonutrition Diet
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Urinary Bladder Neoplasms
×
Disulfides
×
Clear all
NCT07332351
2026-03-13
TRIFECTA
University of Washington
Phase 2
Not yet recruiting
33 enrolled